ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Sen. Bumpers Aims to Raise Health Research $$ With Cuts to Space Station, Supercollider, SDI

April 25, 1992

“Projects For Special Donors” – ACS Considering Way To Raise Vast New Sums For Cancer Program

March 31, 1978

Coalitions Urges Members To Call, Write, Congress

May 3, 1991

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009

NIH Proposes Stricter Rules On Extramural Research Financial Conflicts

May 21, 2010

Clinical Trials Approved By NCI’s CTEP Listed

February 25, 2005